Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | 1.99% | 132.30 | 0.0% | $3021.44m | |
| BNGO | BioNano Genomics, Inc. | 24.32% | 8.64 | 0.0% | $1462.88m | |
| GILD | Gilead Sciences, Inc. | 1.35% | 63.25 | 1.0% | $660.24m | |
| AMGN | Amgen, Inc. | 1.36% | 244.95 | 1.3% | $593.70m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.21% | 156.98 | 2.0% | $543.81m | |
| CRSP | CRISPR Therapeutics AG | -2.17% | 205.48 | 0.6% | $528.15m | |
| NVAX | Novavax, Inc. | -0.28% | 129.62 | 92.9% | $493.87m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.53% | 515.17 | 2.7% | $478.84m | |
| ILMN | Illumina, Inc. | 2.15% | 379.03 | 3.5% | $366.29m | |
| BIIB | Biogen, Inc. | -0.79% | 278.09 | 1.7% | $361.06m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.06% | 226.25 | 1.9% | $344.63m | |
| BNTX | BioNTech SE | -4.58% | 101.00 | 0.0% | $322.68m | |
| SRPT | Sarepta Therapeutics, Inc. | 1.31% | 91.08 | 13.8% | $287.33m | |
| OCGN | Ocugen, Inc. | 5.02% | 2.29 | 0.0% | $283.75m | |
| EDIT | Editas Medicine, Inc. | 6.11% | 80.56 | 7.9% | $260.09m |
Company Profile
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.